Maxwell Lasko
Associate Director Clinical Pharmacology at Kymera Therapeutics | Cambridge, Massachusetts, United States
Maxwell Lasko’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
ContactOut Insights • AI Generated
Maxwell Lasko serves as Associate Director of Clinical Pharmacology at the Cambridge-based Kymera Therapeutics, where he leads clinical pharmacology strategy for the company’s pipeline of oral small molecule degraders. A graduate of Drake University, he supports the translation of Kymera’s targeted protein degradation platform—which has successfully advanced its first degrader into clinical trials for immunological diseases—through rigorous dose-selection and biomarker validation. His daily responsibilities center on generating robust pharmacokinetic and exposure-response data to guide the selection of optimal therapeutic regimens for early-stage patient studies.
BEST APPROACH TO REACH Maxwell Lasko
Given the directory’s strong confidence in direct personal channels, contact him via the on-file mobile number with a concise value proposition tailored to optimizing clinical pharmacology workflows for targeted protein degradation assets.
Associate Director Clinical Pharmacology at Kymera Therapeutics in January 2025 - Present
Senior Scientist - Clinical Pharmacology at Alnylam Pharmaceuticals in January 2023 - January 2025
Clinical Pharmacologist at Alnylam Pharmaceuticals in June 2021 - January 2023
Infectious Diseases Pharmacotherapy Fellow at Hartford Hospital in June 2019 - June 2021
PGY-1 Pharmacy Resident at Aurora Health Care in May 2018 - June 2019
Pharmacy Intern at Hy-Vee, Inc. in March 2014 - January 2018
Drake University, Doctor of Pharmacy (PharmD), August 2026
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on delivering oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years.
Discover more about Kymera Therapeutics
Translational Medicine and Innovation
Associate Director, Translational Medicine at Kymera Therapeutics
(November 2022 – Present)
VP Preclinical Development
VP Preclinical Development at Kymera Therapeutics
(November 2022 – Present)
Executive Director and Head, Proteomics at Kymera Therapeutics | PhD in Biomedical Research
Executive Director at Kymera Therapeutics
(Jul 2024 – Present)
Executive Director, Process Chemistry, Kymera Therapeutics
Vice President at Kymera Therapeutics
(Feb 2025 – Present)
Director, Site Engagement Leads
Director, Site Engagement Leads at Kymera Therapeutics
(Dec 2025 – Present)
Vice President, Medical Affairs
Vice President Medical Affairs at Kymera Therapeutics
(May 2025 – Present)
What is Maxwell Lasko email address?
Email Maxwell Lasko at [email protected] and [email protected]. This email is the most updated Maxwell Lasko's email found in 2026.
What is Maxwell Lasko phone number?
Maxwell Lasko phone number is 8153531535 and 8153637535.
How to contact Maxwell Lasko?
To contact Maxwell Lasko send an email to [email protected] or [email protected]. If you want to call Maxwell Lasko try calling on 8153531535 and 8153637535. (updated on September 16, 2025)
What company does Maxwell Lasko work for?
Maxwell Lasko works for Kymera Therapeutics.
What is Maxwell Lasko's role at Kymera Therapeutics?
Maxwell Lasko is Associate Director Clinical Pharmacology
What industry does Maxwell Lasko work in?
Maxwell Lasko works in the Biotechnology industry.
